Exelixis

February 24, 2020February 24, 2020

Cabometyx-Tecentriq Combo Leads to Lasting Response in Men with Advanced PC, Phase 1b Trial Data Shows

News

The combination of Cabometyx (cabozantinib) and Tecentriq (atezolizumab) is safe and shows clinically meaningful activity, leading to lasting responses in men with metastatic castration-resistant prostate cancer (mCRPC), a Phase 1b trial ... Read more

January 23, 2020January 23, 2020

Exelixis to Expand Group of mCRPC Patients in Phase 1b Trial Testing Cabometyx-Tecentriq Combo

News

Exelixis will expand its Phase 1b clinical trial evaluating a combination of Cabometyx (cabozantinib) with Tecentriq (atezolizumab) to include more patients with metastatic castration-resistant prostate cancer (mCRPC), based on preliminary ... Read more

September 10, 2014September 10, 2014

Cometriq Fails to Meet Primary Endpoint in Metastatic Castration-Resistant Prostate Cancer

News

Exelixis, Inc. has announced the results from its COMET-1 phase 3 trial on cabozantinib for the treatment of metastatic castration-resistant prostate cancer (mCRPC) did not meet the primary endpoint of overall ... Read more